BRISTOL MYERS SQUIBB

The FDA approved Cobenfy, a new schizophrenia treatment with fewer side effects than current drugs, targeting muscarinic receptors instead of dopamine. Marketed by Bristol Myers Squibb, it will be available at $1,850 a month starting in October, with potential for long-term benefits in negative symptoms like apathy and lack of motivation.

Bristol Myers Squibb's Cobenfy gets FDA approval for schizophrenia without elderly mortality warning. HHS declares emergency in Georgia post-Hurricane Helene. Pfizer withdraws Oxbryta for sickle cell disease due to safety concerns. Bird flu risks rise with migration; four Missouri health workers show mild symptoms. Pregnancy sleep deprivation linked to baby brain harm.

BMO Capital raised Bristol-Myers Squibb's price target to $53.00 from $48.00, maintaining a Market Perform rating, following the approval of COBENFY, priced at $1,850/30-day supply. Analysts project COBENFY could reach peak sales of $2.4 billion for Schizophrenia and $3.9 billion for Alzheimer's psychosis, reflecting a more optimistic outlook for the company's financial performance.

FDA approves Bristol Myers Squibb’s COBENFY, a first-in-class muscarinic agonist for schizophrenia in adults, targeting M1 and M4 receptors without blocking D2 receptors, offering a new pharmacological approach after 30 years.

FDA approves Cobenfy, a new oral medication for schizophrenia targeting cholinergic receptors, offering an alternative to traditional antipsychotic drugs. Cobenfy, containing xanomeline and trospium chloride, reduces symptoms without common side effects like weight gain or drowsiness, based on successful phase III clinical trial results published in JAMA Psychiatry.

FDA approves COBENFY, a new oral medication for schizophrenia in adults, marking the first new class of medications for the disorder in decades. COBENFY, developed by Bristol Myers Squibb, offers a novel pharmacological approach and is expected to be available in the U.S. by late October.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, highlighting its role in improving performance and user experience.

FDA approves Cobenfy capsules, a first-in-class muscarinic agonist, for oral treatment of schizophrenia in adults, targeting cholinergic receptors. Efficacy demonstrated in two 5-week, randomized, double-blind, placebo-controlled studies, showing significant symptom reduction.

Bristol Myers Squibb secures FDA approval for Cobenfy, a new schizophrenia drug without mortality risk warnings in elderly patients, offering a safer alternative to existing treatments.

The FDA approved Cobenfy, the first new treatment for schizophrenia in decades, targeting cholinergic receptors instead of dopamine. This new approach offers a significant alternative to existing antipsychotic medications, with studies showing meaningful symptom reduction in patients. However, Cobenfy comes with risks and side effects, including urinary retention and liver damage, limiting its use in certain patient groups. The approval is hailed as a 'monumental step' for schizophrenia patients and their families, with Bristol Myers Squibb launching a support program for those prescribed Cobenfy.